Results 11 to 20 of about 287,802 (318)

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

NEJM Evidence, 2023
Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone.
T. Barbui, A. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, Greta Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G. G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M. Finazzi, G. Tognoni, A. Rambaldi   +37 more
semanticscholar   +1 more source

JAK2V617F allele burden in polycythemia vera: burden of proof

Blood, 2023
Visual ...
A. Moliterno, H. Kaizer, B. Reeves
semanticscholar   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman, T. Barbui   +42 more
semanticscholar   +1 more source

Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin, dizzi

Journal of Bahria University Medical and Dental College, 2021
Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin ...
Nabeela Iqbal, Syed Khalid Shah, Shamima Haneef   +2 more
doaj   +1 more source

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022
TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva‐Kyuchukova, M. Egyed, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, V. Empson, H. Hasselbalch, R. Kralovics, H. Gisslinger, Jean-Jacques Pencho Dorota Liana Miklos Petr Arpad Halyna Lylia Kiladjian Georgiev Krochmalczyk Gercheva-Kyuchukov, J. Kiladjian   +18 more
semanticscholar   +1 more source

Prevalence and diagnostic performance of iron deficiency in polycythemia

Hematology, 2023
Introduction Several observations have shown that patients with polycythemia have iron deficiency. Our objectives were to report the prevalence of iron deficiency and to evaluate the diagnostic performance of serum ferritin in polycythemia vera.Patients ...
Rova Malala Fandresena Randrianarisoa, Herveat Ramanandafy, Alexandre Mania, Hélène Monjanel, Sébastien Trouillier   +4 more
doaj   +1 more source

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Blood Cancer Journal, 2022
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
A. Carobbio, A. Vannucchi, V. De Stefano, A. Masciulli, P. Guglielmelli, G. G. Loscocco, F. Ramundo, E. Rossi, Y. Kanthi, A. Tefferi, T. Barbui   +10 more
semanticscholar   +1 more source

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

Cancer, 2022
Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown.
A. Álvarez-Larrán, M. Garrote, F. Ferrer-Marín, M. Pérez-Encinas, M. Mata-Vázquez, B. Bellosillo, E. Arellano-Rodrigo, Montse Gómez, R. García, V. García‐Gutiérrez, M. Gasior, B. Cuevas, A. Angona, M. Gómez-Casares, C. Martínez, E. Magro, R. Ayala, Rafael del Orbe-Barreto, R. Pérez-López, M. Fox, J. Raya, Lucía Guerrero, C. García-Hernández, G. Caballero, Ilda Murillo, B. Xicoy, M. Ramírez, G. Carreño-Tarragona, J. Hernández‐Boluda, Arturo Pereira   +29 more
semanticscholar   +1 more source

Genetic Background of Polycythemia Vera

Genes, 2022
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the V617F mutation detected in nearly 98% of cases.
Mathilde Regimbeau, Romain Mary, F. Hermetet, F. Girodon   +3 more
semanticscholar   +1 more source